ML281

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

ML281  纯度: 99.88%

ML281是一个强的，有选择性的STK33抑制剂，IC50值是14 nM。

ML281

ML281 Chemical Structure

CAS No. : 1404437-62-2

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ￥990 In-stock
5 mg ￥900 In-stock
10 mg ￥1200 In-stock
50 mg ￥4500 In-stock
100 mg ￥7500 In-stock
200 mg ￥11000 In-stock
500 mg   询价  
1 g   询价  

* Please select Quantity before adding items.

ML281 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Anti-Cancer Compound Library
  • Targeted Diversity Library

生物活性

ML281 is a potent and selective STK33 inhibitor with IC50 of 14 nM. ML281 showed a 550-fold selectivity over AurB and greater than 700-fold selectivity over PKA. target: STK33 IC50: 14 nM [1] ML281 showed low nanomolar inhibition of purified recombinant STK33 and a distinct selectivity profile as compared to other STK33 inhibitors. Even at the highest concentration tested (10 μM), ML281 had no effect on the viability of KRAS-dependent cancer cells. [2]

体外研究
(In Vitro)

ML281 (10 μM; 72 hours) suppresses cell viability of NCI-H446 cells[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[3]

Cell Line: NCI-H446 cells
Concentration: 10 μM
Incubation Time: 72 hours
Result: Suppressed cell viability of NCI-H446 cells.

分子量

389.47

Formula

C22H19N3O2S
CAS 号

1404437-62-2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 100 mg/mL (256.76 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.5676 mL 12.8380 mL 25.6759 mL
5 mM 0.5135 mL 2.5676 mL 5.1352 mL
10 mM 0.2568 mL 1.2838 mL 2.5676 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献

  • [1]. We?wer M et al. A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells. ACS Med Chem Lett, 2012 Dec 13, 3(12):1034-1038.

    [2]. Sun EL, et al. Knockdown of human serine/threonine kinase 33 suppresses human small cell lung carcinoma by blocking RPS6/BAD signaling transduction. Neoplasma. 2017;64(6):869-879.

    [3]. Spoonamore J et al. Screen for Inhibitors of STK33 Kinase Activity. National Center for Biotechnology Information (US); 2010-2011 Dec 16.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务